Search

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US

Read about the approved updates to the PI for Tradjenta® (linagliptin) tablets and Jentadueto® (linagliptin & metformin HCI). View ISI, PI and Med Guide.

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

Fighting Rabies in Madagascar | Boehringer Ingelheim US

Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

Women Inspiring Women: 5 questions for 6 women

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

PI Update for Pradaxa® (dabigatran etexilate) | BI US

Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.

Employees join #stayhomeandfoster movement

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers